{
    "nct_id": "NCT04761198",
    "official_title": "A Phase 1b/2 Open-Label Study of the Efficacy and Safety of Etigilimab (MPH313) Administered in Combination With Nivolumab to Subjects With Locally Advanced or Metastatic Solid Tumors (ACTIVATE)",
    "inclusion_criteria": "* Histological or cytological diagnosis of a relevant tumor type as per the study protocol and not candidates for curative surgery or radiation therapy\n* Available tumor tissue (archival or newly obtained core or excisional biopsy)\n* Adequate hematologic and end organ function as measured by laboratory screening panel in the 14 days prior to treatment\n* Life expectancy greater than 12 weeks.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1\n* Adequate contraception for women of childbearing potential\n* Pre-specified wash-out of prior anti-PD1/PDL-1 therapy\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Concurrent active malignancy\n* Major surgery within 4 weeks of treatment\n* Participants with active, known or suspected autoimmune diseases\n* Prior treatment with cluster of differentiation (CD) 137 agonists, anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT) antibodies\n* History of any Grade 3 or 4 immune-related adverse event (AE) toxicity from prior immunotherapy that resulted in treatment discontinuation\n* History of immune-related adverse events that lead to discontinuation of anti-PD-1 or PDL-1 therapy\n* Active infections of human immunodeficiency virus (HIV), hepatitis B, hepatitis C\n* Medical illness or abnormal laboratory finding that would, in the Study Investigator's judgement, increase the risk to the participant associated with participation in the study\n* Pregnancy in female participants",
    "miscellaneous_criteria": ""
}